Filing Flows › Haemonetics (HAE) › Q2 FY27
Haemonetics (HAE) Q2 FY27 earnings results (second quarter fiscal 2027)
10-Q filed Nov 5, 2026
Haemonetics (HAE) reported revenue of $358M for the second quarter fiscal 2027 (Q2 FY27), +9% from a year earlier and +5% from the quarter before. Operating margin was 21.0%, net earnings $46.3M (12.9% of revenue).
Haemonetics, Q2 FY27: revenue $358M (+9% year over year), operating margin 21.0%, net earnings $46.3M, operating cash flow $128M. The chart follows the revenue to costs, profit and cash.
| Q2 FY27 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $358M | +5% | +9% |
| Gross profit | $221M | +9% | +13% |
| Operating profit | $75.1M | +31% | +28% |
| Net earnings | $46.3M | +40% | +20% |
| Operating cash flow | $128M | +145% | +15% |
| Free cash flow | $113M | +155% | +7% |
What changed
Revenue was $357.8M in Q2 FY27, up 9% year over year and up 5% from the previous quarter. Apheresis was the largest line at 57% of revenue. Apheresis added $23.0M year over year (up 13%), 76% of the total change.
Gross margin was 61.7%, up 2.3 points from Q2 FY26. Operating profit was $75.1M, a 21.0% margin (up 3.1 points year over year). Of the extra revenue versus Q2 FY26, 55% reached operating profit, above the 18% margin then. Operating expenses grew 7% against revenue growth of 9%. The fastest-growing cost line was SG&A (+16%). Net earnings were $46.3M, up 20% year over year. The effective tax rate was 26.3%.
Operating cash flow was $128.1M (up 15% year over year), 277% of net earnings. Non-cash charges added back $27.8M of depreciation and amortization and $10.2M of share-based compensation. Working capital and other items added $43.8M. Capital expenditures of $14.8M left free cash flow of $113.3M.
Questions
What was Haemonetics' revenue in the second quarter fiscal 2027?
Haemonetics (HAE) reported revenue of $358M for the second quarter fiscal 2027 (Q2 FY27), +9% from a year earlier and +5% from the quarter before.
Was Haemonetics profitable in the second quarter fiscal 2027?
Operating profit was $75.1M (21.0% of revenue) and net earnings $46.3M.
Source: Haemonetics 10-Q on SEC EDGAR.